Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?

Article Figures & Data

Table 1.

Targets to be treated for the different features of the disease and consequential potential treatment strategies.

Disease Features	Which Target?	Which Treatment?
Cutaneous involvement	Clear or almost clear skin; PASI75, PASI90, PASI100; BSA < 3%	IL-17 inhibitors IL-12/23 inhibitors Anti-TNF Apremilast MTX Cyclosporine
Enthesitis involvement	No tender and swollen enthesis, LEI ≤ 1, pain-VAS ≤ 15, PtGA ≤ 20	Anti-TNF IL-17 inhibitors IL-12/23 inhibitors JAK inhibitors Apremilast ABA
Articular involvement	No tender and swollen joints, DAPSA ≤ 4, ACR50 criteria, BASDAI ≤ 4 (for axial disease), absence of active dactylitis	MTX Anti-TNF IL-17 inhibitors IL-12/23 inhibitors JAK inhibitors Apremilast ABA
Extraarticular involvement (uveitis, IBD)	No uveitis flares, remission according to composite disease activity indices in IBD	MTX SSZ Anti-TNF (monoclonal antibodies) IL-12/23 inhibitors JAK inhibitors
Systemic involvement (systemic inflammation) Comorbidities	Control of systemic inflammation Reduce comorbidities in the future or better control of current comorbidities	Targeting key cytokines and cellular pathways

PASI: Psoriasis Area Severity Index; BSA: body surface area; IL: interleukin; TNF: tumor necrosis factor; LEI: Leeds Enthesitis Index; VAS: visual analog scale; PtGA: patient’s global assessment; DAPSA: Disease Activity in Psoriatic Arthritis; ACR50 criteria: American College of Rheumatology 50% criteria; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; IBD: inflammatory bowel disease; MTX: methotrexate; ABA: abatacept; JAK: Janus kinase; SSZ: sulfasalazine.